Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib-Reference-Cited by-同舟云学术

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib

Published:2011-08-25 Issue:9 Volume:109 Page:1349-1354
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Yuasa Takeshi,Tsuchiya Norihiko,Urakami Shinji,Horikawa Yohei,Narita Shintaro,Inoue Takamitsu,Saito Mitsuru,Yamamoto Shinya,Yonese Junji,Fukui Iwao,Nakano Kenji,Takahashi Shunji,Hatake Kiyohiko,Habuchi Tomonori

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2011.10534.x/fullpdf

Reference21 articles.

1. Novel therapeutics for metastatic renal cell carcinoma;Hutson;Cancer,2009

2. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities;Christensen;Ann Oncol,2007

3. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

4. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009

5. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety;Uemura;Jpn J Clin Oncol,2010

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer;Kidney Cancer;2022-11-18

2. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients;Anticancer Research;2018-01-02

3. Preoperative evaluation of renal cell carcinoma patients with bone metastases on risks for blood loss, performance status and lethal event;Journal of Orthopaedic Science;2017-09

4. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study;Pharmacoepidemiology and Drug Safety;2017-06-01

5. Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors;Journal of Oncology Pharmacy Practice;2017-02-20